Opens in a new tab

Can Umbilical Cord Stem Cells Help Restore Fertility? A New Clinical Study Explores the Possibility

When the Uterine Lining Struggles to Recover

The human body has an impressive ability to repair itself, but some tissues face challenges when healing from injury. For women experiencing certain fertility conditions, damage to the uterine lining can make becoming pregnant particularly difficult.

One example is Asherman syndrome, a condition in which scar tissue develops inside the uterus. This can interfere with the growth of the endometrium, the specialized lining that prepares for pregnancy. When this lining remains unusually thin despite conventional treatment, the condition is known as refractory thin endometrium.

A 2025 study published in Stem Cells Translational Medicine investigated whether umbilical cord-derived mesenchymal stem cells (UC-MSCs) could help improve this challenging condition.

A Unique Approach to Tissue Repair

Researchers explored a treatment combining human umbilical cord-derived mesenchymal stem cells with a collagen scaffold.

Collagen is a structural protein naturally found throughout the body. In this study, it served as a supportive framework designed to hold the cells in place within the uterus.

The researchers developed an approach they described as “farming therapy.”

First, surgeons removed existing adhesions and carefully prepared the affected tissue. They then placed the collagen scaffold containing UC-MSCs into the uterine cavity. The goal was to create a more favorable environment for endometrial recovery, potentially improving the conditions needed for embryo implantation.

Inside the Clinical Trial

The double-blind, randomized controlled trial took place at Xiangya Hospital in China. Researchers enrolled 25 women with infertility and persistent endometrial thinning. One participant withdrew before treatment, leaving 24 women who received the assigned interventions.

Participants were divided into two groups:

  • UC-MSC group: 11 women received surgical treatment followed by a collagen scaffold containing umbilical cord-derived stem cells.
  • Control group: 13 women received the same surgical treatment followed by a collagen scaffold containing saline instead.

Researchers monitored endometrial thickness, pregnancy outcomes, live births, and treatment safety.

Encouraging Signs for Pregnancy Outcomes

The results revealed several interesting differences between the groups. Three of the 11 women receiving UC-MSCs experienced a live birth, compared with one of the 13 women in the control group. This represented cumulative live-birth rates of 27.3% and 7.7%, respectively.

Researchers also observed differences in clinical pregnancy rates:

  • 45.5% in the UC-MSC group.
  • 7.7% in the control group.

Although these results were encouraging, neither difference reached statistical significance. The small number of participants makes it difficult to determine whether the treatment itself produced the improvements.

Nevertheless, the findings provide a reason to investigate the approach in larger clinical trials.

Did the Uterine Lining Improve?

Researchers also measured changes in endometrial thickness, an important consideration when evaluating uterine conditions associated with infertility. In the UC-MSC group, average endometrial thickness increased from 5.3 millimeters before treatment to 6.5 millimeters afterward. This improvement was statistically significant within the treatment group.

The control group also experienced an increase, from 5.3 to 6.0 millimeters, although that change was not statistically significant. Importantly, the difference in improvement between the two groups was not statistically significant.

Additional laboratory analysis suggested that the treatment may influence cellular communication pathways involved in immune activity and embryo implantation.

What Did Researchers Find About Safety?

The treatment demonstrated encouraging initial safety findings. No serious adverse events were reported following UC-MSC scaffold transplantation. Some participants experienced temporary symptoms, including dizziness, nausea, and mild abdominal discomfort.

Two women in the UC-MSC group developed urticaria, commonly known as hives, which resolved within several days without special treatment.

Researchers considered the treatment relatively safe during the study’s follow-up period, while emphasizing the importance of additional long-term monitoring.

A New Direction for Regenerative Medicine

One of the most interesting aspects of this research is its combination of cellular therapy and tissue engineering. Rather than administering stem cells alone, scientists used a biological scaffold designed to support their placement within damaged tissue.

Although the study did not establish that UC-MSCs improved live-birth rates, the observed pregnancy outcomes and changes in endometrial thickness offer an encouraging foundation for future research.

Larger trials will be necessary to determine whether this approach can meaningfully improve fertility outcomes and establish its long-term safety.

For now, the research highlights an intriguing possibility: regenerative medicine may eventually offer new ways to support tissue recovery in reproductive health.

Source

Hou Z, Yang T, Xu D, et al. hUC-MSCs loaded collagen scaffold for refractory thin endometrium caused by Asherman syndrome: a double-blind randomized controlled trial. Stem Cells Translational Medicine. 2025;14(4). DOI: 10.1093/stcltm/szaf011
Full study: https://pmc.ncbi.nlm.nih.gov/articles/PMC12079654/

Do you have questions?

We have answers. Speak with a Stemedix Care Coordinator today with no obligation. Give us a call!

Contact Us
Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.